Virax Biolabs Group Overview
Virax Biolabs Group (VRAX) has a ROE of -146.29%, below the sector sector average of -4.03%.
Get informed when a big investor buys or sells
+ Follow-146.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VRAX is -146.29%. That is below the sector sector average of -4.03%. Investors often review this figure alongside Virax Biolabs Group's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, VRAX currently prints -146.29% for ROE, while the sector average sits near -4.03%. That is roughly 3534.6% below the sector mean. Large gaps often invite a closer look at Virax Biolabs Group's growth, margins, and balance sheet.
Return on Equity shows how effectively Virax Biolabs Group converts resources into returns. At -146.29%, VRAX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VRAX's ROE (-146.29%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
